GLP-1 Drug Exenatide Improved Both Raised Brain Pressure and Polycystic Ovary Syndrome in a Young Woman Through Direct Receptor Effects | Research

The takeaway

Exenatide, a GLP-1 receptor agonist peptide, improved headaches and double vision from idiopathic intracranial hypertension and restored menstrual cycles in a patient with PCOS — with brain pressure improvements occurring before significant weight loss.

Improvement before weight loss
Headaches and double vision improved early after starting exenatide, suggesting direct GLP-1 receptor effects on brain fluid production rather than weight-mediated benefits

What the researchers found

A 29-year-old woman with PCOS and IIH without papilledema (IIHWOP) was treated with exenatide after intolerance to acetazolamide. Key findings:

- Headache frequency and diplopia (double vision) improved early, independent of weight loss, suggesting direct receptor-mediated reduction of cerebrospinal fluid secretion and intracranial pressure

- Menstrual cycles and hormonal profile improved beyond the effects of metformin alone

- Insulin resistance improved

- The patient had gained 15 kg over eight months prior to treatment

- IIH was diagnosed by MRI (enlarged pituitary fossa, partial empty sella, optic nerve sheath dilatation) and lumbar puncture showing raised opening pressure of 280 mmH₂O with normal CSF composition

Why it matters

IIH and PCOS frequently co-occur in young obese women but are typically treated with different medications. The discovery that GLP-1 receptors are present on choroid plexus cells (which produce cerebrospinal fluid) and ovarian tissue suggests that GLP-1 peptide drugs could treat both conditions simultaneously through direct receptor effects — not just through weight loss. This opens a new therapeutic application for GLP-1 agonists and could simplify treatment for patients with both conditions.

How the study worked

Single-patient case report documenting clinical course after initiating exenatide for a patient with both IIH and PCOS. Diagnosis was confirmed by ophthalmic examination, MRI, and lumbar puncture. Clinical outcomes tracked included headache frequency, visual symptoms, menstrual regularity, hormonal profile, and insulin resistance markers.

What this study cannot tell us

This is a single case report (n=1), the weakest form of clinical evidence. Causation cannot be established — improvements could be coincidental or related to other factors. The early headache improvement attributed to direct receptor effects was inferred but not confirmed by repeat lumbar puncture or intracranial pressure monitoring. The degree to which improvements in PCOS symptoms exceeded metformin's effects alone is difficult to quantify in a single patient. Longer follow-up is needed to assess sustained benefit.

How to read the evidence

This is a single case report — the lowest tier of clinical evidence. It generates an interesting hypothesis about direct GLP-1 receptor effects on intracranial pressure but cannot establish efficacy or causation.

When this study was published

Published in 2025, this case report reflects the growing interest in GLP-1 agonist applications beyond diabetes and obesity, particularly in neurological and reproductive conditions.

The bigger picture

This case adds to the rapidly expanding list of conditions where GLP-1 receptor agonists show unexpected benefits. The finding that exenatide directly reduces intracranial pressure through choroid plexus receptors is particularly striking, as it demonstrates that GLP-1 peptide receptors in the brain serve functional roles beyond appetite regulation. If confirmed in larger studies, GLP-1 agonists could become a unified treatment for the metabolic-neurological-reproductive syndrome that many young obese women experience.

Questions still open

Would a randomized trial of GLP-1 agonists for IIH confirm the direct intracranial pressure-lowering effect seen in this case?
Is exenatide specifically better than other GLP-1 agonists (semaglutide, liraglutide) for IIH due to its receptor binding characteristics at the choroid plexus?
Could GLP-1 agonists replace acetazolamide as first-line therapy for IIH in obese women with concurrent PCOS?

Common questions

What is idiopathic intracranial hypertension and how could a GLP-1 drug help?

IIH is abnormally high pressure inside the skull that causes severe headaches, vision problems, and can lead to blindness. GLP-1 receptors have been found on the choroid plexus — the tissue that produces cerebrospinal fluid. Exenatide may directly reduce fluid production and lower brain pressure, separate from its weight loss effects.

Can one drug treat both brain pressure problems and PCOS?

This case suggests it might. GLP-1 receptors exist in both the brain's fluid-producing tissue and the ovaries. Exenatide appeared to improve intracranial pressure symptoms and restore menstrual cycles through direct receptor effects at both sites, making it a potential dual-purpose treatment for these commonly co-occurring conditions.

Read the original research

The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report.

Cureus, 17(10), e93846

View on PubMed ↗Publisher’s paper ↗

Citation

Nicolaou, Despina; Nicolaou, Nicolas; Douglas, Lisa M; Christou, Savvas. (2025). The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report.. Cureus, 17(10), e93846. https://doi.org/10.7759/cureus.93846